The Role of Luteolin in Inhibiting Prostaglandin‐Endoperoxide Synthase 2 to Relieve Neointimal Hyperplasia in Arteriovenous Fistula
Authors:
- 17 February 2025
- journal article
- Published by Wiley in Advanced Biology
- Vol. 9 (4) , e2400437
Abstract
This study aims to investigate the role and mechanism of luteolin in inflammation and phenotypic switch of vascular smooth muscle cells (VSMCs) in an arteriovenous fistula (AVF) model, for providing a potential agent for the prevention and therapy of AVF neointimal hyperplasia. In vivo, an AVF model is created in Sprague Dawley rats. In vitro, rat VSMCs are treated with platelet‐derived growth factor‐BB (PDGF‐BB) to induce the phenotypic switch of VSMCs. Histological AVF changes are analyzed using hematoxylin‐eosin. Western blot and quantitative real‐time polymerase chain reaction (qRT‐PCR) are utilized to detect prostaglandin‐endoperoxide synthase 2 ( PTGS2 ) expression. In vivo, luteolin inhibits neointima formation and reduces vimentin, α‐SMA, MCP‐1, MMP‐9, TNF‐α, and IL‐6 levels. In vitro, under PDGF‐BB treatment, luteolin inhibits proliferation and migration and reduces TNF‐α, vimentin, α‐SMA, MCP‐1, MMP‐9, and IL‐6 levels in VSMCs. In rat AVF tissues, PTGS2 expression is increased. Luteolin inhibits PTGS2 expression in vivo and in vitro. PTGS2 overexpression reverses the role of luteolin in extracellular matrix protein expression, proliferation, inflammation, and migration in VSMCs treated with PDGF‐BB. Altogether, in the AVF, luteolin inhibits proliferation, migration, the phenotypic switch of VSMCs, neointima formation, and the inflammatory response through inhibiting PTGS2 expression.Keywords
This publication has 45 references indexed in Scilit:
- Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researchesPhytotherapy Research, 2023
- Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 yearsActa Pharmaceutica Sinica B, 2022
- Luteolin as a modulator of skin aging and inflammationBioFactors, 2020
- Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF‐κB signaling pathwayJournal of Cellular Physiology, 2019
- Luteolin, a flavonoid, as an anticancer agent: A reviewBiomedicine & Pharmacotherapy, 2019
- Local Adipose-Associated Mediators and Adaptations Following Arteriovenous Fistula CreationKidney International Reports, 2018
- Arteriovenous fistula stenosis in hemodialysis patients is characterized by an increased adventitial fibrosisJournal Of Nephrology, 2014
- Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases2011
- Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1–5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesiaEuropean Journal of Pharmacology, 2010
- Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for HemodialysisJAMA, 2008